Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Recursion Pharmaceuticals : Berenberg Bank Initiates Coverage on Recursion Pharmaceuticals With Buy Rating, $37 Price Target

09/21/2021 | 07:58am EST


© MT Newswires 2021
All news about RECURSION PHARMACEUTICALS, INC.
09:51aRecursion Pharmaceuticals to Expand Fibrosis Collaboration With Bayer to Include Infere..
MT
08:02aRECURSION PHARMACEUTICALS : and Bayer Expand Fibrosis Collaboration to Include Inferential..
PU
07:57aRECURSION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
07:56aRecursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabil..
PR
11/30Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Sen..
PR
11/30Recursion Enhances Its Leadership Team and Deepens Focus on Neuroscience with Three Sen..
CI
11/10Health Care Stocks Outlasting Declining Biotechs
MT
11/10Health Care Stocks Slightly Higher Amid Market Malaise Wednesday
MT
11/10Recursion Q3 Loss Narrows as Revenue Improves
MT
11/10RECURSION PHARMACEUTICALS : Q3 Earnings Snapshot
AQ
More news
Analyst Recommendations on RECURSION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 10,4 M - -
Net income 2021 -169 M - -
Net cash 2021 318 M - -
P/E ratio 2021 -14,4x
Yield 2021 -
Capitalization 2 995 M 2 995 M -
EV / Sales 2021 256x
EV / Sales 2022 256x
Nbr of Employees 330
Free-Float 77,7%
Chart RECURSION PHARMACEUTICALS, INC.
Duration : Period :
Recursion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECURSION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 17,72 $
Average target price 33,20 $
Spread / Average Target 87,4%
EPS Revisions
Managers and Directors
Chistopher C. Gibson Chief Executive Officer & Director
Tina Larson President & Chief Operating Officer
Michael Secora Chief Financial Officer
Ramon Martin Chavez Márquez Independent Chairman
Benjamin Mabey Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
RECURSION PHARMACEUTICALS, INC.0.00%2 995
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.47%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819